ResMed Inc. (NYSE:RMD) Stock Holdings Increased by Yousif Capital Management LLC

Yousif Capital Management LLC increased its stake in shares of ResMed Inc. (NYSE:RMD) by 0.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,482 shares of the medical equipment provider’s stock after purchasing an additional 101 shares during the quarter. Yousif Capital Management LLC’s holdings in ResMed were worth $5,033,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of ResMed by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 18,173,462 shares of the medical equipment provider’s stock valued at $4,156,089,000 after buying an additional 160,590 shares during the period. Geode Capital Management LLC increased its stake in shares of ResMed by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider’s stock worth $899,860,000 after acquiring an additional 85,270 shares during the last quarter. Invesco Ltd. raised its holdings in shares of ResMed by 32.2% during the fourth quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider’s stock worth $531,706,000 after acquiring an additional 566,046 shares in the last quarter. Northern Trust Corp boosted its position in ResMed by 20.6% during the fourth quarter. Northern Trust Corp now owns 1,702,590 shares of the medical equipment provider’s stock valued at $389,365,000 after purchasing an additional 290,664 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in ResMed by 3.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 957,020 shares of the medical equipment provider’s stock valued at $218,861,000 after purchasing an additional 32,973 shares in the last quarter. 54.98% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $219.74, for a total transaction of $439,480.00. Following the sale, the director now directly owns 73,218 shares in the company, valued at approximately $16,088,923.32. The trade was a 2.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Michael J. Farrell sold 8,009 shares of the company’s stock in a transaction on Monday, June 9th. The shares were sold at an average price of $251.21, for a total value of $2,011,940.89. Following the completion of the transaction, the chief executive officer now owns 455,503 shares of the company’s stock, valued at $114,426,908.63. The trade was a 1.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,132 shares of company stock worth $7,075,837 in the last ninety days. 0.71% of the stock is currently owned by insiders.

ResMed Stock Down 0.6%

ResMed stock opened at $251.18 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. ResMed Inc. has a fifty-two week low of $179.42 and a fifty-two week high of $263.05. The firm has a fifty day moving average price of $235.14 and a two-hundred day moving average price of $234.83. The firm has a market cap of $36.83 billion, a price-to-earnings ratio of 29.65, a P/E/G ratio of 1.53 and a beta of 0.78.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.01. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The business had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter in the previous year, the firm earned $2.13 EPS. The firm’s revenue was up 7.9% compared to the same quarter last year. As a group, analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Thursday, May 8th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 0.84%. The ex-dividend date is Thursday, May 8th. ResMed’s payout ratio is currently 23.79%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Citigroup raised ResMed from a “neutral” rating to a “buy” rating in a research note on Wednesday, March 5th. Morgan Stanley set a $286.00 price objective on shares of ResMed and gave the company an “overweight” rating in a research report on Tuesday, May 20th. JPMorgan Chase & Co. boosted their target price on shares of ResMed from $286.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, April 24th. Wall Street Zen lowered shares of ResMed from a “buy” rating to a “hold” rating in a research note on Saturday, May 24th. Finally, Mizuho set a $265.00 price objective on shares of ResMed in a research note on Wednesday, April 16th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, ResMed presently has a consensus rating of “Moderate Buy” and an average target price of $259.33.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.